Evidence map›Paper›PMID 41271821›Full record

ArticleNPJ genomic medicine2025

Improving polygenic risk score based drug response prediction using transfer learning.

Youshu Cheng, Song Zhai, Wujuan Zhong, Rachel Marceau West, Judong Shen

Registry-linked trialAbstract read
In one paragraph

Article in NPJ genomic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00202878. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00202878 phase3completed

A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial - IMPROVE IT)

Ran2005Enrolled18,144Registered outcomes4Posted comparisons4ConditionsHypercholesterolemia, Myocardial InfarctionArmsezetimibe/simvastatin, Placebo for ezetimibe 10 mg/simvastatin 40 mg combination, Placebo for simvastatin 40 mg, simvastatin
Open the trial in the graph
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Youshu Cheng *Department of Biostatistics, Yale University, New Haven, CT, USA.
Song Zhai *Biostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, NJ, USA.
Wujuan ZhongBiostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, NJ, USA.
Rachel Marceau WestBiostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, NJ, USA.
Judong ShenBiostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, NJ, USA. judong.shen@merck.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Traditional methods for pharmacogenomics (PGx), like those using disease-specific polygenic risk scores (PRS-Dis), often fail to capture the full heritability of drug response, leading to poor predictions. Direct PGx PRS approaches could improve this, but the scarcity of relevant PGx datasets limits the wide application. To overcome these challenges, we introduce PRS-PGx-TL, a novel transfer learning method. It models large-scale disease summary statistics data alongside individual-level PGx data, leveraging both sources to create more accurate prognostic and predictive polygenic risk scores. In PRS-PGx-TL, we further develop a two-dimensional penalized gradient descent algorithm that starts with weights from disease data and then optimizes them using cross-validation. In simulations and an application to IMPROVE-IT (ClinicalTrials.gov, NCT00202878, September 13, 2005) PGx GWAS data, PRS-PGx-TL significantly enhances prediction accuracy and patient stratification compared to traditional PRS-Dis methods. Our approach shows great promise for advancing precision medicine by using an individual's genetic information to guide treatment decisions more effectively.

Identifiers

PMID41271821
PMCPMC12638960

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.